CanBas' CBP501 meets mesothelioma endpoint
CanBas Co. Ltd. (Tokyo:4575) said CBP501 plus cisplatin and pemetrexed met the primary endpoint of a progression-free survival rate greater than 55% at four months in a Phase II trial to treat malignant pleural mesothelioma (MPM). Specifically, the combination produced a four-month PFS rate of 68%. Additionally, CBP501 plus cisplatin and pemetrexed led to median PFS of 6.4 months vs. 4.7 months for cisplatin and pemetrexed alone, while median overall survival (OS) was 15 months for CBP501 plus chemotherapy vs. 11.2 months for chemotherapy alone. Best objective response rate was 32% in patients receiving CBP501 plus chemotherapy vs. 14% for chemotherapy alone. CanBas said the sample size of the trial was insufficient to determine statistical significance between treatment arms for the median PFS, OS and ORR endpoints. CanBas was off Y14 to Y474 on Monday. ...